Company profile: Endevica Bio
1.1 - Company Overview
Company description
- Provider of biotechnology therapeutics for cachexia and obesity via melanocortin receptor modulation. Offerings include TCMCB07 (B07), a clinical-stage MC3R/MC4R antagonist to treat cancer-related uncontrolled weight loss, shown to increase body weight in chemotherapy and CKD models; MC4R agonists for obesity matching GLP-1 weight loss efficacy in rats without significant weight rebound post-treatment; and novel synthetic peptidomimetics.
Products and services
- TCMCB07 (B07): Clinical-stage antagonist of MC3R and MC4R engineered to treat cancer cachexia, shown to increase body weight in chemotherapy and CKD models
- Novel Synthetic Peptidomimetics: Custom-engineered molecules that interact with complex biological processes, focusing on peptides modulating melanocortin receptors for various therapeutic indications within targeted receptor signaling
- MC4R Agonists: Receptor-targeted MC4R agonists architected for obesity treatment, matching GLP-1 weight loss efficacy in rats and exhibiting no significant weight rebound after treatment in rat studies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Endevica Bio
Nerio Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology for the life sciences sector; founded in 2019 and based in La Jolla, CA, USA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nerio Therapeutics company profile →
CoRegen
HQ: United States
Website
- Description: Provider of SRC-3 and Treg-focused therapies: SRC-3 KO Treg Therapy that engineers Treg cells to infiltrate and destroy tumors; an SRC-3 small molecule inhibitor that blocks transcriptional activity to inhibit cancer growth and boost immune response; an SRC-3 small molecule enhancer to reduce inflammation and improve tissue repair in myocardial infarction and stroke; and Treg engineering.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CoRegen company profile →
Olaris
HQ: United States
Website
- Description: Provider of metabolomics and machine learning-based disease diagnosis and treatment solutions, including Olaris CEREBRO for metabolite profiling to identify individual molecular profiles, myOLARIS diagnostics, a suite of in vitro diagnostic products to optimize patient-specific treatments and outcomes, and Biomarkers of Response (BoRs) technology to determine which patients will benefit from specific therapies and reduce adverse events.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Olaris company profile →
Cernostics
HQ: United States
Website
- Description: Provider of molecular diagnostic tests for cancer, leveraging its patent-protected TissueCypher platform. TissueCypher is a laboratory-developed test that analyzes tissue from Barrett's esophagus biopsies to provide a patient's five-year risk of progression to high-grade dysplasia or esophageal adenocarcinoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cernostics company profile →
Mainz Biomed
HQ: Germany
Website
- Description: Provider of molecular genetic diagnostic solutions for early cancer detection, including ColoAlert, a non-invasive at-home PCR-based colorectal cancer screening test; eAArly DETECT, a multimodal test combining FIT, mRNA biomarkers and AI to differentiate CRC, advanced and non-advanced adenomas; PancAlert, an early-stage pancreatic cancer screening test in development; and ReconAAsense, an FDA PMA pivotal study for next-gen colorectal screening approval.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mainz Biomed company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Endevica Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Endevica Bio
2.2 - Growth funds investing in similar companies to Endevica Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Endevica Bio
4.2 - Public trading comparable groups for Endevica Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →